Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35285853/
Importance: Older patients and those with comorbidities who are infected with SARS-CoV-2 may be at increased risk of hospitalization and death. Sotrovimab is a neutralizing antibody for the treatment of...
Conclusions and relevance: Among nonhospitalized patients with mild to moderate COVID-19 and at risk of disease progression, a single intravenous dose of sotrovimab, compared with placebo, significantly reduced the risk of a composite end point of all-cause hospitalization or death through day 29. The findings support sotrovimab as a treatment...
Meaning: Evidence supports that strongyloidiasis prevalence interacts with the RR of mortality in ivermectin trial results; no evidence was found to suggest ivermectin has any role in preventing mortality in patients with COVID-19 in regions where strongyloidiasis is not endemic.
Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis
Source : https://doi.org/10.1136/bmj-2021-068373
Objective To study the association between covid-19 vaccines, SARS-CoV-2 infection, and risk of immune mediated neurological events. Design Population based historical rate comparison study and self-controlled case series analysis. Setting...
Conclusions: No safety signal was observed between covid-19 vaccines and the immune mediated neurological events of Bell’s palsy, encephalomyelitis, Guillain-Barré syndrome, and transverse myelitis. An increased risk of Bell’s palsy, encephalomyelitis, and Guillain-Barré syndrome was, however, observed for people with SARS-CoV-2...
Discussion: This study found a low risk of myocarditis after a third dose of BNT162b2 in Israeli military recruits. The incidence was lower than observed a week after a second dose of the vaccine in a similar Israeli military population (5.07 per 100 000 vaccines).4 However, the myocarditis incidence for 18- to 24-year-old men was higher than...
Natural COVID-19 antibodies lasts seven months for children, according to new study
Source : https://www.sciencedaily.com/releases/2022/03/220318131640.htm
Children previously infected with COVID-19 develop natural circulating antibodies that last for at least seven months, according to a new study led by researchers at UTHealth Houston. The study was...
“Adult literature shows us that natural infection, plus the vaccine-induced protection, gives you the best defense against COVID-19. There has been a misunderstanding from some parents who think just because their child has had COVID-19, they are now protected and don’t need to get the vaccine. While our study is encouraging in that some...